Cargando…

Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)

BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of AT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zscharnack, Matthias, Krause, Christoph, Aust, Gabriela, Thümmler, Christian, Peinemann, Frank, Keller, Thomas, Smink, Jeske J., Holland, Heidrun, Somerson, Jeremy S., Knauer, Jens, Schulz, Ronny M., Lehmann, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445304/ https://www.ncbi.nlm.nih.gov/pubmed/25990108 http://dx.doi.org/10.1186/s12967-015-0517-x

Ejemplares similares

Surgery Versus ATMPs: An Example From Ophthalmology
por: Magrelli, Federica M., et al.
Publicado: (2020)

Molecular Imaging of Stem Cells: Tracking Survival, Biodistribution, Tumorigenicity, and Immunogenicity
por: Gu, Eugene, et al.
Publicado: (2012)

An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant
por: Bartz, Christoph, et al.
Publicado: (2016)

Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells
por: Thäte, Claudia, et al.
Publicado: (2021)

Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
por: Seimetz, Diane, et al.
Publicado: (2019)

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
por: Detela, Giulia, et al.
Publicado: (2019)

Mini Cleanroom for the Manufacture of Advanced Therapy Medicinal Products (ATMP): Bioengineered Corneal Epithelium
por: Berisa-Prado, Silvia, et al.
Publicado: (2021)

Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson’s Disease to the Clinic: The Investigator’s Perspective
por: Barker, Roger A., et al.
Publicado: (2021)

ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature
por: Damerval, Margaux, et al.
Publicado: (2021)

Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson’s Disease
por: Garitaonandia, Ibon, et al.
Publicado: (2016)

Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease
por: Woods, Niamh, et al.
Publicado: (2020)

Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)—An Indian Perspective
por: Muthu, Sathish, et al.
Publicado: (2022)

Biodistribution of Mesenchymal Stem/Stromal Cells in a Preclinical Setting
por: Sensebé, Luc, et al.
Publicado: (2013)

Comparative strategies for stem cell biodistribution in a preclinical study
por: Wang, Fang, et al.
Publicado: (2019)

Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
por: Vervaeke, P., et al.
Publicado: (2022)

RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe—Why the European Union Should Invest More!
por: Goldsobel, Gady, et al.
Publicado: (2021)

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations
por: Salazar-Fontana, Laura I.
Publicado: (2022)

Preclinical Study on Biodistribution of Mesenchymal Stem Cells after Local Transplantation into the Brain
por: Bashyal, Narayan, et al.
Publicado: (2023)

Regulatory-Compliant Validation of a Highly Sensitive qPCR for Biodistribution Assessment of Hemophilia A Patient Cells
por: Bittorf, Patrick, et al.
Publicado: (2020)

ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing
por: Silva, D.N., et al.
Publicado: (2022)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing
por: Walcher, Lia, et al.
Publicado: (2021)

Quality assessment tests for tumorigenicity of human iPS cell-derived cartilage
por: Takei, Yoshiaki, et al.
Publicado: (2020)

Temporomandibular Joint Osteoarthritis: Regenerative Treatment by a Stem Cell Containing Advanced Therapy Medicinal Product (ATMP)—An In Vivo Animal Trial
por: Köhnke, Robert, et al.
Publicado: (2021)

Abstract 16 New Advanced Therapy Medicinal Products (ATMPs) in Medical Trials: A FamiCord Group Development Pipeline Update
por: Gerth, André, et al.
Publicado: (2022)

“I just wanted to speak to someone- and there was no one…”: using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients
por: Litchfield, Ian, et al.
Publicado: (2023)

Evaluating Ecological Impact and Sustainability in the Manufacturing of Advanced Therapies: Comparative Analysis of Greenhouse Gas Emissions in the Production of ATMPs in Open and Closed Systems
por: Pinnetta, Giuseppe, et al.
Publicado: (2023)

Toxicology and Biodistribution: The Clinical Value of Animal Biodistribution Studies
por: Silva Lima, Beatriz, et al.
Publicado: (2018)

Preclinical Studies for Cartilage Repair: Recommendations from the International Cartilage Repair Society
por: Hurtig, Mark B., et al.
Publicado: (2011)

Preclinical Pharmacokinetics and Biodistribution of Anticancer Dinuclear Palladium(II)-Spermine Complex (Pd(2)Spm) in Mice
por: Vojtek, Martin, et al.
Publicado: (2021)

Preclinical Pharmacokinetics, Biodistribution, and Acute Toxicity Evaluation of Caerin 1.9 Peptide in Sprague Dawley Rats
por: Yang, Xiaodan, et al.
Publicado: (2022)

Rapamycin and the transcription factor C/EBPβ as a switch in osteoclast differentiation: implications for lytic bone diseases
por: Smink, Jeske J., et al.
Publicado: (2009)

Enzyme Replacement in a Human Model of Mucopolysaccharidosis IVA In Vitro and Its Biodistribution in the Cartilage of Wild Type Mice
por: Dvorak-Ewell, Melita, et al.
Publicado: (2010)

Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic
por: Richter, Maximilian, et al.
Publicado: (2016)

Preclinical Study of (68)Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs
por: Naderi, Mojdeh, et al.
Publicado: (2016)

Systematic Review: Allogenic Use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM) as Advanced Therapy Medicinal Products (ATMP) in Tissue Regeneration
por: Gentile, Pietro, et al.
Publicado: (2020)

Process data of allogeneic ex vivo-expanded ABCB5(+) mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP
por: Ballikaya, Seda, et al.
Publicado: (2020)

Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial
por: McMullan, Christel, et al.
Publicado: (2023)

In silico identification and in vitro assessment of a potential anti-breast cancer activity of antimicrobial peptide retrieved from the ATMP1 Anabas testudineus fish peptide
por: Law, Douglas, et al.
Publicado: (2023)

Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits
por: Eldesouky, Lubna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5thqsudskj67et8n8q8vu9lhbc